MARKET

ENTA

ENTA

Enanta Pharmaceuticals Inc
NASDAQ
53.73
+2.47
+4.82%
Closed 16:15 10/04 EDT
OPEN
52.18
PREV CLOSE
51.26
HIGH
54.20
LOW
52.18
VOLUME
152.17K
TURNOVER
--
52 WEEK HIGH
102.00
52 WEEK LOW
37.59
MARKET CAP
1.11B
P/E (TTM)
-9.1705
1D
5D
1M
3M
1Y
5Y
Enanta starts mid-stage trial of EDP-938 for RSV infection
Enanta Pharmaceuticals (NASDAQ:ENTA) <a href="https:...
Seekingalpha · 1d ago
BRIEF-Enanta Pharmaceuticals Initiates A Phase 2B Clinical Study Of EDP-938
BRIEF-Enanta Pharmaceuticals Initiates A Phase 2B Clinical Study Of EDP-938
Reuters · 1d ago
Enanta Pharmaceuticals Initiates A Phase 2b Clinical Study Of EDP-938 In High-Risk Adults With Respiratory Syncytial Virus
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the initiation of a Phase 2b,
Benzinga · 1d ago
Enanta Pharmaceuticals Begins Phase 2b Trial of EDP-938 to Treat Respiratory Syncytial Virus Infection
Enanta Pharmaceuticals Begins Phase 2b Trial of EDP-938 to Treat Respiratory Syncytial Virus Infection
MT Newswires · 1d ago
BRIEF-Enanta Pharma Presents Preclinical Data For Its Respiratory Syncytial Virus And Human Metapneumovirus Programs At 12th International RSV Symposium
BRIEF-Enanta Pharma Presents Preclinical Data For Its Respiratory Syncytial Virus And Human Metapneumovirus Programs At 12th International RSV Symposium
Reuters · 5d ago
Enanta Pharmaceuticals Presenting Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium
Enanta Pharmaceuticals, Inc.
Benzinga · 5d ago
Akero adds over 100% rallying peers after NASH success
Akero Therapeutics (NASDAQ:AKRO), a biotech focused on n...
Seekingalpha · 09/13 16:08
Enanta Pharmaceuticals Says New Preclinical Data For EDP-235, Co's Oral Coronavirus Protease Inhibitor Designed For Treatment Of COVID-19, To Be Presented At IDWeek 2022
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data for
Benzinga · 09/07 12:32
More
About ENTA
Enanta Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in development of small molecule drugs for the treatment of viral infections and liver diseases. The Company has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). The Company has discovered glecaprevir, a protease inhibitor discovered and developed for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET. Its product candidates also include EDP-514, EDP-305 and EDP-938. The Company's subsidiary is Enanta Pharmaceuticals Security Corporation.

Webull offers kinds of Enanta Pharmaceuticals Inc stock information, including NASDAQ:ENTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENTA stock methods without spending real money on the virtual paper trading platform.